Hemispherx BioPharma, Inc (AMEX:HEB) Finally Rebounds on Non-News

The news was mediocre at best, yet Hemispherx BioPharma, Inc. (AMEX: HEB) shares are up a solid 12% after the company announced a response to issues raised regarding Ampligen as a treatment for chronic fatigue syndrome. The FDA, in simplest terms, needed more information about the drug's preclinical data. The response was inevitable, yet sparked a rally the day it was released.

That said, odds are good that Hemispherx BioPharma, Inc. shares were going to rally back anyway. HEB had found support at $0.57 for the better part of December, and had even tested bullish waters a couple of times. The news was simply the catalyst that may well get the HEB ball rolling again. And there's certainly plenty of room to recover.